Freestone Grove Partners LP Neurocrine Biosciences Inc Transaction History
Freestone Grove Partners LP
- $9.71 Trillion
- Q1 2025
A detailed history of Freestone Grove Partners LP transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Freestone Grove Partners LP holds 5,209 shares of NBIX stock, worth $640,863. This represents 0.01% of its overall portfolio holdings.
Number of Shares
5,209Holding current value
$640,863% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding NBIX
# of Institutions
649Shares Held
97.2MCall Options Held
749KPut Options Held
553K-
Black Rock Inc. New York, NY14.2MShares$1.75 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.94MShares$1.22 Billion0.02% of portfolio
-
Dodge & Cox San Francisco, CA5.53MShares$681 Million0.37% of portfolio
-
State Street Corp Boston, MA4.86MShares$598 Million0.02% of portfolio
-
Jpmorgan Chase & CO New York, NY2.67MShares$329 Million0.02% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $11.8B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...